Article
Cell Biology
Beverly Brooks, Dominique Ebedes, Ahsan Usmani, Joaquin Vega Gonzales-Portillo, Daniel Gonzales-Portillo, Cesario Borlongan
Summary: Ischemic brain injury is a major cause of death worldwide with limited treatment options. Stem cell-based regenerative therapies, specifically mesenchymal stromal cells, show promise in stroke treatment, but further research is needed to fully understand their cell function.
Review
Cell Biology
Yuchang Liu, Minrui Wang, Yang Yu, Chunhong Li, Chunxiang Zhang
Summary: Acute myocardial infarction, characterized by irreversible cardiomyocyte death and restricted blood supply, is the leading cause of death in coronary heart disease. Conventional reperfusion therapy can worsen myocardial injury. Stem cell therapy using mesenchymal stem cells (MSCs) has emerged as a promising approach for cardiac repair and function improvement. MSCs may exert their effects by secreting exosomes containing therapeutically active RNA, proteins, and lipids. Analyzing these vesicles can provide valuable insights into myocardial infarction pathology and guide the development of new treatments.
CELL COMMUNICATION AND SIGNALING
(2023)
Review
Immunology
Chang Liu, Kun Xiao, Lixin Xie
Summary: Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a common and highly fatal condition. Current treatment options lack specificity and effectiveness. However, studies have shown that mesenchymal stem cells (MSCs) can improve the prognosis of ALI/ARDS by regulating macrophage polarization balance.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Jia Li, Yuling Huang, Haiyan Sun, Lina Yang
Summary: Mesenchymal stem cells (MSCs) from multiple tissues have the capability of multidirectional differentiation and self-renewal, and their derived exosomes (MSC-Exos) may have a real role to play in treating age-related diseases. The review focuses on the biological characteristics of MSCs and exosomes, their mechanisms in treating age-related diseases, current trials, ongoing clinical trials, and the prospects and challenges for the future use of exosomes in disease treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Neurosciences
Yu Xiong, Jianping Song, Xinyue Huang, Zhigang Pan, Roland Goldbrunner, Lampis Stavrinou, Shu Lin, Weipeng Hu, Feng Zheng, Pantelis Stavrinou
Summary: Ischemic stroke is a condition caused by impaired cerebral blood supply, and current treatment strategies are limited. Exosomes, nano-sized biovesicles, have the potential to be a therapeutic modality for ischemic stroke.
FRONTIERS IN NEUROSCIENCE
(2022)
Review
Genetics & Heredity
Huarui Cai, Zhongze Wang, Wenhan Tang, Xiaoxue Ke, Erhu Zhao
Summary: This review discusses the role of mTOR in mesenchymal stem cells and its potential for treating ageing-related diseases.
FRONTIERS IN GENETICS
(2022)
Review
Pharmacology & Pharmacy
Zhimin Yang, Yanyu Li, Zihua Wang
Summary: Exosomes are important communication carriers between cells and can be used for disease diagnosis and treatment. MSCs-Exo, as a natural drug delivery carrier, has therapeutic effects and is increasingly used in the treatment of cardiovascular diseases and neurodegenerative diseases.
Review
Medicine, General & Internal
Ya Yang, Yalei Zhao, Lingjian Zhang, Fen Zhang, Lanjuan Li
Summary: Mesenchymal stem cell (MSC) transplantation is a novel treatment for liver diseases, but the mechanisms are not fully understood. Despite significant efficacy in animal models and preliminary clinical trials, issues such as efficacy and safety remain. Therefore, more research is needed to address the challenging issues of MSC-based therapy in the treatment of liver diseases.
FRONTIERS IN MEDICINE
(2021)
Review
Immunology
Yuanliang Xia, Jianshu Zhu, Ruohan Yang, Hengyi Wang, Yuehong Li, Changfeng Fu
Summary: Spinal cord injury (SCI) has a significant impact on patient health, and the use of mesenchymal stem cells (MSCs) shows promise in treating SCI. Preclinical studies have shown positive results, but the effectiveness of MSCs in clinical practice remains controversial. More research is needed to address the challenges and potential applications of MSCs in the treatment of SCI.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Xiao-Yu He, Hai-Ming Yu, Shu Lin, Yi-Zhong Li
Summary: Osteoporosis is a severe public health concern among the elderly and postmenopausal adults, with related fractures posing a major cause of morbidity and mortality. Emerging technologies for treating osteoporosis, such as mesenchymal stem cells, exosomes, and biomimetic materials, have received increasing research attention and shown significant progress in reconstruction and repair of bones affected by osteoporosis-related fractures.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2021)
Review
Cell Biology
Yuhe Jiang, Ping Zhang, Xiao Zhang, Longwei Lv, Yongsheng Zhou
Summary: Osteoporosis is a systemic metabolic bone disease characterized by bone loss and microstructural degeneration, leading to increasing personal and societal costs. MSC transplantation shows promising potential in treating osteoporosis, but issues such as safety, transplant efficiency, and standardization of the manufacturing process need to be addressed. Comprehensive evaluation of clinical trials is essential for clinical translation of MSC therapy for osteoporosis.
CELL PROLIFERATION
(2021)
Review
Immunology
Yuhao Chen, Lihong Yang, Xihong Li
Summary: This review discusses the mechanisms and signaling pathways involved in the modulation of macrophage polarization by mesenchymal stem cells (MSCs), providing innovative directions for the treatment of sepsis-induced liver injury.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Carl Randall Harrell, Vladislav Volarevic, Valentin Djonov, Ana Volarevic
Summary: AT-MSC-Exos are potential therapeutic agents for neural and retinal diseases by delivering neurotrophins, immunoregulatory factors, and pro-angiogenic miRNAs to alleviate inflammation and promote cell survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Qianqian Yu, Han Wang, Lingling Zhang, Wei Wei
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is commonly used to treat hematological malignancies and genetic diseases, with graft-versus-host disease (GVHD) being a common complication leading to severe morbidity and mortality. Current first-line therapeutic drugs for GVHD prevention and treatment are corticosteroids, but a significant number of patients develop steroid-refractory GVHD with poor prognosis. Various immune cells, such as Tregs, Bregs, and mesenchymal stromal cells (MSCs), have shown benefit in GVHD prevention and therapy, but further research is needed to optimize treatment strategies and improve patient prognosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Hao Chen, Liangfu Zhou
Summary: Ischemic stroke is a major cause of death and disability, and mesenchymal stem cell (MSC) therapy holds promise as a treatment modality. However, the therapeutic effect of MSCs is limited in the harsh microenvironment of ischemic brain tissue. Modified MSC therapy has shown better outcomes under different pathological conditions, and is expected to be translated into clinical practice.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2022)
